Wellinks Raises $10M Series B Led by UMass Memorial Health

Wellinks has raised the first close of a $10M Series B led by UMass Memorial Health, with participation from existing inside investors. The New Haven, Connecticut-based digital health company is focused on virtual cardiopulmonary care for chronic obstructive pulmonary disease, or COPD, and congestive heart failure, or CHF. The financing supports commercial growth and Wellinks' push toward predictive patient care, where remote monitoring is supposed to do more than collect another mountain of data for clinicians who already have enough tabs open.

The investor matters almost as much as the money. UMass Memorial Health already has a multiyear commercial relationship with Wellinks, putting a health system on both sides of the relationship as strategic investor and commercial partner. Healthcare has produced enough beautiful decks describing theoretical efficiencies to wallpaper a hospital. Capital coming from an organization already working with the company is a more interesting signal. The broader Wellinks story is about remote patient monitoring moving from documenting what happened toward identifying what may happen next, early enough for clinicians to potentially do something about it.

What Happened

Wellinks announced the first close of a $10M Series B led by UMass Memorial Health, with existing inside investors also participating. The financing extends the existing commercial relationship between the 2 organizations and gives Wellinks additional capital for commercial growth, predictive care and expansion beyond COPD into CHF.

Wellinks previously raised $25M in a 2021 financing described at the time as a Series C led by Morningside, with participation from HighCape Capital, Connecticut Innovations, Benslie International, Digitalis Ventures, MPM Capital and Stonehenge Capital. The sequence is unusual because Wellinks describes the August 2026 financing as a Series B first close despite the earlier Series C designation. That distinction is worth stating plainly rather than quietly forcing the company's financing history into a cleaner chronology than the public record provides.

Why This Matters

Wellinks is targeting one of digital health's harder problems: proving that continuous monitoring can change what happens to patients rather than simply produce more information about them. The company's Spire RPM System uses passive wearable Spire Tags to monitor respiratory and physiologic signals and is designed to identify deterioration up to 1 week before symptoms emerge. The strategic question is whether those signals can help clinical teams intervene before chronic disease turns into expensive acute care.

Research cited by Wellinks associates Spire RPM with 45% fewer COPD-related emergency room visits, 65% fewer hospitalizations and average annual savings of $11.3K per patient. Wellinks also says fewer than 4% of eligible COPD patients have access to pulmonary rehabilitation. Those figures frame the economic argument around the platform. Collecting data is not inherently progress. Healthcare has plenty of data and remarkably little spare time. The value appears when information changes a clinical decision early enough to matter.

Market Context

Wellinks has assembled its current cardiopulmonary platform partly through acquisitions. The company acquired Spire Health in September 2024, bringing wearable respiratory-monitoring technology into Wellinks, and acquired Sparo's Lift pulmonary rehabilitation program in February 2025. The resulting model combines monitoring, predictive signals and virtual pulmonary rehabilitation around chronic cardiopulmonary disease rather than treating each component as an isolated digital-health product.

Distribution is the other half of the equation. Wellinks has established relationships with healthcare organizations including CareAbout Health, SoNE HEALTH and UMass Memorial Health. That matters because healthcare technology does not win merely by being technically elegant. It has to survive procurement, reimbursement, clinical workflow and institutional politics, preferably without making physicians hate another login before breakfast.

The Wellinks Story and Leadership

Wellinks traces its roots to a Yale startup co-founded by Ellen Su in 2013. The original business developed Cinch, a connected scoliosis-brace compliance device, before being acquired by Convexity Scientific in 2020. The combined business subsequently adopted the Wellinks name and concentrated on virtual COPD care. The corporate path is not particularly tidy, which is another way of saying it resembles an actual startup rather than the version eventually compressed into 4 slides for investors.

According to the Wellinks leadership information, Jennifer Barretta currently serves as Interim CEO and COO alongside Ilaa Atluru, EVP Finance, and Stephanie Solich, VP Customer Success. Ellen Su remains relevant to the founding history but is no longer part of the current operating leadership. Wellinks' current leadership information does not identify a CTO, so DevCuration is not assigning that title to an individual without authoritative confirmation.

Competitive Landscape

Wellinks sits at the intersection of remote patient monitoring, virtual specialty care, wearable health technology, chronic disease management and value-based healthcare. That makes its competitive problem more complicated than selling better hardware. Wellinks has to show that passive monitoring, predictive analytics and clinical support can work together in a system that providers can use and payers can economically justify.

Expansion from COPD into CHF makes that test more consequential. Moving into another cardiopulmonary condition is not simply a matter of adding a disease name to the product page. Clinical pathways, intervention models and patient populations differ. Wellinks is effectively testing whether its model of continuous monitoring and earlier intervention can travel across related chronic conditions without losing the clinical and economic logic that made the original proposition interesting.

What This Signals

The $10M Wellinks financing reflects a broader digital-health market that is becoming less impressed by standalone technology and more interested in integrated clinical infrastructure. Remote patient monitoring answered the question, what is happening with this patient outside the clinic? Predictive care attempts the harder question: what may happen next, and can somebody act before it becomes an emergency?

UMass Memorial Health leading the Series B does not independently prove that Wellinks will scale. It does make the financing more informative than a venture round detached from commercial use. Wellinks has combined acquired technology, provider relationships and an existing strategic health-system partnership before raising additional capital. For founders and investors, the lesson is less glamorous than startup mythology: solve an expensive problem, demonstrate clinical usefulness, build distribution and give capital evidence worth following.

The Bigger Industry Shift

The deeper market movement is from remote patient monitoring toward predictive patient care. Data collection was phase 1. Turning those signals into useful decisions is the harder phase. Healthcare makes that transition particularly unforgiving because predictive technology cannot merely sound intelligent. Clinical usefulness, workflow integration, economics and patient outcomes eventually get a vote.

For providers and payers, the Wellinks thesis comes down to a straightforward question: can predictive cardiopulmonary care identify deterioration early enough to improve outcomes and reduce expensive acute utilization? Wellinks now has another $10M and a strategic health-system investor behind its attempt to answer it. That makes this financing less interesting as another line on a funding leaderboard and more interesting as a test of where remote care goes after monitoring alone stops being enough.